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Validation of molecular genetic analytical methods has to be part of basic practice in
clinical-diagnostic laboratories that are working in compliance with the ISO15189
guidelines (www.iso.org). Moreover, OECD has issued “Guidelines for Quality
Assurance in Molecular Genetic Testing (www.oecd.org/sti/biotechnology)” which
stipulate that laboratories providing clinical services should be working within a
“Quality Assurance System”. In this regard, these laboratories should demonstrate
that a given method is reliable, precise and robust. However, the ISO norm does not
stipulate which validation parameters and to which extent these should be evaluated.
Thus, it is up to individual laboratories to establish an acceptable validation process
in order to comply with general principles of the ISO norm. Here we report
practical examples of validation procedures utilized for a “home brew” technique
versus approaches applied to a commercially produced assay (ASR). For CF DNA
diagnostics quality assurance it is crucial to establish such a procedure for the major
CFTR allele F508del that is examined in our laboratory by PCR-related fragment
analysis with ﬂuorescently labeled primers using the ABI 3130 genescanner for
capillary electrophoresis. Validation of the SALSA P091 MLPA assay for the
detection of large rearrangements in the CFTR gene serves as another example.
In both instances we assessed basic validation parameters including speciﬁcity,
sensitivity, repeatability, reproducibility and robustness. These procedures helped
us to conﬁrm diagnostic reliability of both techniques and provide an example for
other laboratory procedures employed in CF DNA diagnostics.
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Real-time PCR has proven to be a useful method to quantify gene expression in
samples with small number of cells. We have applied this technology to validate
the relative quantiﬁcation of RNA CFTR from nasal brushing of CF patients
in a Taqman assay (ABI 7300). Four endogenous genes have been evaluated
(HPRT1, beta2-M, GUSB, PMCA4). Standard curves were performed for CFTR
and endogenous genes from the cell line HEK293 over expressing CFTR, nasal
polyp and nasal epithelial (NE) samples. The selection of suitable endogenous
genes for normalization is a prerequisite for accurate determination of expression
level. Hence, PCR efﬁciencies have been determined and two different software
programs (NormFinder, qBase) have been used to evaluate expression stability in
NE samples from CF patients (n = 9) and controls (n = 9). DNAs from all individuals
were analyzed for CFTR gene. RNA quality was determined and only samples with
a RIN above 5.2 were included. The experiment has been carried out twice from
two independent RT reactions and each sample was analyzed in triplicate. We have
identiﬁed three endogenous genes suitable for accurate normalization of CFTR data
expression.
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Background: The implication of R117H mutation on CF phenotype remains unex-
plained. Phenotypic heterogeneity of R117H/(other severe CFTR mutation) genotype
is explained by additional effect of the polyT tract in intron 8 (IVS8-T). The R117H+7T
or 9T/F508del genotype is known to be responsible for CBAVD in most cases.
According to different research and clinical groups, only R117H with 5T variant in cis
is considered to be a CF-causing mutation.
Aim: To evaluate the impact of R117H+7T or 9T variant on clinical status.
Methods: The group of 9 patients (4 with CF, 5 with azoospermia) with
R117H+7T or 9T/(other CFTR mutation) genotype were examined. Clinical data of
all patients were collected between Nov 2006 and Jan 2007. Retrospective study was
carried out comparing: pulmonary function, pancreatic and bacteriological status.
Conclusion: The R117H mutation, without IVS8−5T variant, is responsible for either
CFTR related disorders (i.e. azoospermia and CBAVD) or typical/atypical forms of CF.
Thus, we propose to include the R117H mutation in common CFTR mutation panel
during diagnostic procedure both in standard (based on clinical status) and newborn
screening programme.
Molecular and clinical results
Genotype Onset of
disease
BMI
[kg/m2]
Cl−
[mmol/l]
FEV1
[%]
X-ray
results
Pancreatic
status [PI/PS]
Bacteriological
status
Patients with male infertility
F508del/R117H 7T/7T 34th yr 23.6 13.5 no data abnormal PS no data
F508del/R117H 7T/9T 25th yr 24.9 75.1 105 normal PS no data
F508del/R117H 7T/9T 29th yr 24.2 81.0 113 normal PS no data
F508del/R117H 7T/9T 30th yr 23.9 37.8 95 normal PS no data
F508del/R117H 7T/9T 32nd yr 26.0 76.7 94 abnormal PS no data
Cystic ﬁbrosis patients
G542X/R117H 7T/9T 3rd moa 17.1 28.6 no data abnormal PI/PS physiological ﬂora
L138ins/R117H 7T/7T 9th yr 20.92 67.0 106 normal PI physiological ﬂora
F508del/R117H 7T/9T 1st moa 15.3 44.2 no data abnormal PI physiological ﬂora
F508del/R117H 7T/9T 1st moa 18.1 29.0 no data abnormal PI physiological ﬂora
aNewborn screening.
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CF phenotypes are very variable, also when originating from identical CFTR geno-
types. This topic can be dissected into two levels that can be called “biochemical”
and “clinical”. The former level relates to the consequences of CFTR mutations on
chloride efﬂux, whereas the latter relates to the link between chloride levels and
clinical symptoms.
Among the large number of CFTR mutations with controversial functional effect,
we selected the (TG)12T5 and the L997F. For both we found a signiﬁcantly higher
frequency in atypical CF forms than in the general population. We studied, in
13 subjects with genotype (TG)12T5/classic mutation (= mut) and in 11 subjects
with genotype L997F/mut, the biochemical effect on the sweat test (as an in vivo
measure of CFTR functionality), relating it to genotypes. Sweat test values were
highly variable: from 20 to 90 mEq/L in the (TG)12T5/mut group and from 19 to 102
mEq/L in the L997F/mut group. These values were only partially related to the kind
of classic mutations present. Also clinical presentations exhibited a high variability,
showing only a limited correlation to the sweat test values. The phenotypes of the
(TG)12T5/mut group ranged from strictly mono- to poly-symptomatic with pancreas
insufﬁciency; the L997F/mut group spanned from near normal phenotypes to cases
with pulmonary involvement.
A preliminary analysis evidenced, in some cases, the presence of additional CFTR
sequence variations in cis, introducing variability at the biochemical level. This
search is actually under completion.
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